Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Summary

This Phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant. Patients receiving a donor stem cell transplant may experience accelerated bone loss and an increase risk of bone fractures, leading to a decrease in satisfaction and quality of life. A type of immunotherapy drug called denosumab binds to a protein called RANKL, which may help keep bone from breaking down.

Timeline

Start

2019-12-19

Primary completion

2022-11-16

Completion

2022-11-16

Drugs

Indications